“Fresh frozen plasma (FFP) is one of the most commonly prescribed hemostatic agents in clinical practice globally. Main FFP indications include acquired deficiency of multiple coagulation factors during active bleeding, bleeding prevention, and therapeutic plasma exchange (TPE). Patients with thrombotic thrombocytopenic purpura (TTP) require recurrent TPE and account for significant plasma usage (average 40 L per admission). Appropriate use of plasma transfusion is key in patient blood management to adequately restore hemostatic function and impact subsequent blood component requirements. However, plasma transfusion has various challenges, including ABO incompatibility, pathogen transmission, transfusion complications (e.g., transfusion-related acute lung injury [TRALI] or transfusion-associated circulatory overload [TACO]), anaphylactic reactions, and storage/logistical issues. Suboptimal hemostatic management can increase blood component usage, further risking patient safety and inflating costs. Advances in patient blood management may improve patient outcomes and have economic benefits.”

Racine-Brzostek SE, Cushing MM, Gareis M, Heger A, Mehta Shah T, Scully M. Thirty years of experience with solvent/detergent-treated plasma for transfusion medicine. Transfusion. 2024 Apr 21. doi: 10.1111/trf.17836. Epub ahead of print. PMID: 38644541.